PMID- 28994614
OWN - NLM
STAT- MEDLINE
DCOM- 20180814
LR  - 20221207
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 13
IP  - 24
DP  - 2017 Oct
TI  - Meta-analysis for the efficacy of S-1-based regimens as the first-line treatment 
      in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer.
PG  - 2195-2207
LID - 10.2217/fon-2017-0214 [doi]
AB  - AIM: We performed a meta-analysis to evaluate the efficacy and safety for 
      S-1-based regimens as the first-line treatment in Asian chemotherapy-naive 
      patients with advanced non-small-cell lung cancer. PATIENTS & METHODS: Eligible 
      randomized clinical trials (RCTs) were included, of which data were extracted by 
      inclusion criteria and exclusion one. Odds ratio and hazard ratio (HR) of 
      outcomes including objective response rate (ORR), progression-free survival 
      (PFS), overall survival (OS) and adverse effects (AEs) were explored for the 
      final analysis. RESULTS: Twenty-one RCTs including 3263 patients were fit into 
      the analysis. Pooled HR for PFS was 1.01 (95% CI: 0.92-1.10; p = 0.88), the 
      pooled HR for OS was 0.95 (95% CI: 0.85-1.06; p = 0.33) and the pooled odds ratio 
      for ORR was 0.74 (95% CI: 0.61-0.90; p = 0.003). S-1-based regimens showed milder 
      AEs in high-grade nausea/vomit, anorexia, leukopenia, neutropenia and febrile 
      neutropenia (all p < 0.05). CONCLUSION: The present study has revealed that 
      S-1-based regimens are accompanied by the similar efficacy and slighter AEs 
      compared with standard regimens as the first-line treatment in Asian 
      chemotherapy-naive patients with advanced non-small-cell lung cancer.
FAU - Chen, Jianxin
AU  - Chen J
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      324000, China.
FAU - Wang, Junhui
AU  - Wang J
AD  - Department of Radiation Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      324000, China.
FAU - Wu, Xilin
AU  - Wu X
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      324000, China.
FAU - Che, Xiaoling
AU  - Che X
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      324000, China.
FAU - Zou, Yan
AU  - Zou Y
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      324000, China.
FAU - Weng, Meiling
AU  - Weng M
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      324000, China.
FAU - Miao, Qian
AU  - Miao Q
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      324000, China.
FAU - Zheng, Qinhong
AU  - Zheng Q
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      324000, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20171010
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Asian People
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/*pathology
MH  - Clinical Trials as Topic
MH  - Drug Combinations
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/*pathology
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Odds Ratio
MH  - Oxonic Acid/administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Tegafur/administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Asian chemotherapy-naive patients
OT  - S-1
OT  - first-line treatment
OT  - non-small-cell lung cancer
EDAT- 2017/10/11 06:00
MHDA- 2018/08/15 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2018/08/15 06:00 [medline]
PHST- 2017/10/11 06:00 [entrez]
AID - 10.2217/fon-2017-0214 [doi]
PST - ppublish
SO  - Future Oncol. 2017 Oct;13(24):2195-2207. doi: 10.2217/fon-2017-0214. Epub 2017 
      Oct 10.